Menu
RESEARCH FUNDING
Real World Evidence of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis (worldwide)
The Real World Evidence of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis research grant from Pfizer seeks to generate new Real World Evidence (RWE) in the management of atopic dermatitis (AD) with abrocitinib. Applications are open to researchers based in countries where abrocitinib is approved. The applicant (PI) must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy. Applicant must be affiliated with a host institution.
Applicants may apply for up to 175,000 USD for up to 9 months (including 28% indirect costs).
Applications are due on January 11, 2024.
Full application due:
January 11, 2024
January 11, 2024
